Evidence map›Paper›PMID 41665072›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma.

Frederico O Gleber-Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Frederico O Gleber-NettoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0001-7847-9902
Deborah SilvermanDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tongxin XieDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shamima AkhterDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicole R VaughnDepartment of Leukemia and Division of Cancer Medicine, The University of TX MD Anderson Cancer Center, Houston, TX, USA.
Adewale AdebayoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kala Chand DebnathDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shorook NaaraDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shajedul IslamDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Erik KnutsenDepartment of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
Emily Lorin AshkinDepartment of Cancer Immunology and Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
Simone AnfossiDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sara LeaheyDepartment of Cancer Immunology and Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
Patrick HwuDepartment of Cancer Immunology and Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
Sebastien TalbotDepartment of Pharmacology and Physiology, Karolinska Institute, Stockholm, Sweden.
Erica K SloanMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Robert Saddawi-KonefkaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roberto RangelDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
George A CalinDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Moran AmitDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-9720-7766

Funding

Harnessing the nervous system to overcome resistance to immunotherapy in oral cancerR01DE032018 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Moran Amit, George A. Calin · 2022 to 2026
$3.5M
Ben and Catherine Ivy FoundationCanada Foundation for Innovation 44135Canadian Cancer Society Emerging Scholar Research 708096CIHR 407016CIHR 461274CIHR 461275G. Harold & Leila Y. Mathers Foundation, Brain SPORE 2P50CA127001Knut and Alice Wallenberg Foundation KAW2021.0141Knut and Alice Wallenberg Foundation KAW2022.0327MD Anderson Cancer Center Institutional Research 600382301249242National Institute of Health, National Cancer Institute R371R37CA242006-01A1Natural Sciences and Engineering Research Council of Canada NIH/NIDCRR01DE032712Natural Sciences and Engineering Research Council of Canada RGPIN-2019-06824NIDCR NIH HHS R01 DE032018NIDCR NIH HHS R01DE032018Swedish Research Council 2022-01661U.S. Department of Defense CA200990P2
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is notoriously resistant to immunotherapy. The interplay between β-adrenergic signaling and p53 loss, both key regulators of immune responses, has remained largely unexplored in the setting of tumor-immune evasion. This study demonstrates that pharmacologic stimulation of β2-adrenergic receptors with isoprenaline significantly enhances cytotoxic T cell activity against p53-deficient HNSCC cells via a CXCL10-dependent paracrine mechanism. Comprehensive transcriptomic and co-culture assays reveal that p53-null cancer cells upregulate CXCL10, which promotes CD8

Indexed as

Mouth NeoplasmsReceptors, Adrenergic, betaSquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p53AnimalsCell Line, TumorChemokine CXCL10HumansMiceMice, KnockoutSignal TransductionTumor MicroenvironmentChemokine CXCL10Receptors, Adrenergic, betaTumor Suppressor Protein p53CXCL10head and neck cancerneuroscienceβ‐adrenergic signaling

Identifiers

PMID41665072
PMCPMC13292172

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.